4-Bromo-1,3-Thiazole-2-Carboxaldehyde

During a 200 L scale campaign to produce a pre-clinical kinase inhibitor candidate structurally related to fedratinib, 4-bromo-1,3-thiazole-2-carboxaldehyde served as the eastern fragment in a palladium-mediated Suzuki-Miyaura assembly. The coupling partner was 4-(4-methylpiperazin-1-ylmethyl)phenylboronic acid pinacol ester. To suppress proto-debromination — a persistent side reaction attributable to residual water and basic hydrolysis of the aldehyde — the aldehyde was charged at 1.00 equivalent with the boronic ester at 1.12 equivalents, Pd(PPh₃)₄ at 0.0075 equivalents, and anhydrous K₃PO₄ at 2.5 equivalents in degassed 1,4-dioxane (8.0 L/kg aldehyde). The mixture was stirred at 82 ± 2 °C under an argon blanket in a glass-lined reactor equipped with a retreat-curve impeller. Aqueous work-up with 5% w/w NaCl and dichloromethane extraction, followed by treatment with SiliaMetS® Thiol resin (10% w/w relative to crude mass, batch mode at 50 °C for 4 h), reduced residual palladium from 340 ppm to 3.2 ppm. The isolated off-white solid was crystallized from ethyl acetate/n-heptane (1:3 v/v) to yield 76–81% across 14 production batches with an HPLC purity (USP <621>, C18, 254 nm) exceeding 99.2 area%. The pharmaceutical intermediate required compliance with ICH Q3C for residual solvents (dioxane ≤ 380 ppm, ethyl acetate ≤ 5000 ppm) and ICH Q3D for elemental impurities; the oral PDE for palladium was set at 100 µg/day, necessitating the thiol resin treatment as a routine step. The single greatest operational bottleneck was the exothermic decomposition of the aldehyde under prolonged basic conditions: aliquots showed 0.8–1.4% conversion to 4-bromothiazole-2-carboxylic acid after 6 h at pH > 10.5, requiring the addition rate of the boronic ester to be extended over 45 min and the internal temperature kept below 85 °C.

In a distinct pharmaceutical programme targeting a fused pyrimidine scaffold, the formyl group was employed in a reductive amination sequence. The substrate was dissolved in tetrahydrofuran (6.0 L/kg) and charged with N-Boc-cadaverine (1.05 eq). Sodium triacetoxyborohydride (1.4 eq) was added portion-wise at 15–20 °C to minimize dibenzylation and concomitant reduction of the C–Br bond, which becomes kinetically competitive when local temperatures exceed 25 °C. Glacial acetic acid (0.1 eq) was introduced to maintain the pH at 4.5–5.0; a drift below 4.0 accelerated borohydride decomposition, while exceeding 6.0 slowed iminium formation. After 18 h at ambient temperature, the reaction was quenched with saturated NaHCO₃ and extracted into ethyl acetate. GC headspace analysis confirmed residual THF ≤ 0.02% after drying at 40 °C (−0.08 MPa). The resulting secondary amine was telescoped into a copper-catalyzed Ullmann coupling with iodoimidazole without isolation of the free base. Here, the bromine substituent remained intact during the borohydride step, a selectivity confirmed by single-ion recording LC/MS; loss of bromine was quantified at < 0.3%. This route supplied a multi-kilogram batch of the penultimate intermediate for a Phase II asset, with the overall four-step yield from the title aldehyde calculated at 52%.

What Residual Palladium Thresholds Are Realistically Achievable When This Aldehyde Is Used as a Regulatory Starting Material?

Regulatory starting material designation under ICH Q11 places stringent purity expectations on 4-bromo-1,3-thiazole-2-carboxaldehyde, particularly when introduced in the final chemical transformation step of a GMP sequence. The bromothiazole is intrinsically a palladium sponge due to the heterocyclic nitrogen and the aldehyde carbonyl, forming soluble complexes that escape filtration through Celite®. A comparative study across three commercial catalysts on a 20 g laboratory scale, with Pd loading fixed at 0.5 mol% in a Suzuki coupling with 3-cyanophenylboronic acid, exposed pronounced differences in post-workup metal content. A dry powder scrub with QuadraPure™ TU resin delivered the most consistent depletion of palladium below the element-specific limit for parenteral products (10 µg/day permitted daily exposure, ICH Q3D Option 1). The aldehyde function was temporarily protected as the bisulfite adduct during the metal scavenging step to preclude thiol-aldehyde adduct formation; after acidification and extraction, the recovered aldehyde exhibited no detectable loss of purity. Residual formaldehyde from adduct hydrolysis was purged by azeotropic distillation with acetonitrile to ≤ 50 ppm. The entire sequence was validated in a 50 L Hastelloy reactor with inert FEP-lined dip tubes, where the palladium content of the final dried solid reached 0.8–1.4 ppm in routine batches.

Downstream, the 4-bromothiazole unit has been functionalized through lithiation-electrophile quench chemistry to access 5-substituted regioisomers difficult to obtain by direct halogenation. In a well-chilled 100 L cylindrical vessel fitted with a calibrated PT100 thermocouple, a solution of the aldehyde in anhydrous THF (8 L/kg) was treated with lithium diisopropylamide (1.05 eq, freshly prepared from n-BuLi and diisopropylamine at −20 °C) at −78 ± 3 °C. The deprotonation at the 5-position proceeded with visual colour change to deep amber within 15 min. Addition of iodomethane (1.5 eq) as electrophile, followed by gradual warming to −10 °C over 3 h, afforded 4-bromo-5-methylthiazole-2-carboxaldehyde after aqueous NH₄Cl quench and distillation of solvents. Analytical yield by calibrated GC-FID reached 84%; the major impurity (7.2%) resulted from aldol self-condensation of the aldehyde, catalysed by residual amine. This side reaction could be suppressed to < 2% by rigorously drying the LDA solution over molecular sieves 4A and maintaining the aldehyde substrate concentration below 0.20 M. The 5-methyl derivative subsequently served as the core heterocycle in a series of dopamine D₃ receptor ligands, its methyl group providing a metabolic soft spot assessed in human liver microsome stability assays (t_1/2 38 min vs. 9 min for the non-methylated analogue).

In agrochemical discovery, the aldehyde serves as a precursor to thiazole oxime ether fungicides that mimic the Mode of Action of QoI strobilurins. The carbonyl is first condensed with methoxylamine hydrochloride (1.2 eq) in pyridine/ethanol (1:4 v/v) at reflux for 2 h to give the O-methyl oxime, followed by nucleophilic aromatic substitution of the 4-bromo with 2,6-difluorophenol under phase-transfer conditions (K₂CO₃ in DMF, 100 °C, tetrabutylammonium bromide 0.05 eq, 8 h). The differential reactivity between bromine displacement and oxime hydrolysis is critically narrow; water content in DMF must be kept below 0.02% by Karl Fischer titration to prevent conversion of the oxime back to the aldehyde, which then oligomerizes in hot basic media. After quenching into ice-water, the crude oxime ether was purified by medium-pressure liquid chromatography (Biotage® Isolera, silica 60 µm, ethyl acetate/heptane gradient) to 98.7% LCAP and dosed into a greenhouse leaf-disc assay against Phytophthora infestans, exhibiting EC₅₀ values in the 0.8–2.3 mg/L range across five replicates. The toxicity of the synthetic intermediate to aquatic organisms warranted classification under GHS Category Acute 2 (LC₅₀/96 h rainbow trout 1.4 mg/L), trigged by the unreacted bromothiazole aldehyde present at 0.3% in the technical material.

When the Aldehyde Is Used as an Orthogonal Click Handle in Cellular Thermal Shift Assay Probe Construction

4-Bromo-1,3-thiazole-2-carboxaldehyde has been adopted by chemical biology groups as a dual-reactive building block for generating target-engagement probes where the formyl group is ligated to an alkoxyamine-modified biotin tag and the bromine is reserved for on-DNA Suzuki diversification in a DNA-encoded library (DEL) setting. The oxime ligation was performed in ammonium acetate buffer at pH 4.8 with 1.5 equivalents of a PEG4-linked aminoxybiotin, achieving > 95% conversion in 2 h at 37 °C without observable hydrolysis of the DNA-attached bromothiazole. Crucial for the reliability of the subsequent on-DNA Suzuki with a panel of arylboronic acids was the removal of excess hydroxylamine and aniline by-products (from reagent degradation) by spin filtration with a 3 kDa molecular weight cut-off centrifugal device; residual nucleophiles reduced coupling efficiency by 40–60% through catalyst chelation. All manipulations complied with the precautionary risk assessment for potentially mutagenic azides and boronic acids (ECHA Annex VI, category 2 skin sensitisers). The final biotinylated conjugate exhibited a mass recovery of 78% after RP-HPLC purification and was validated in a CETSA® assay format, where a thermal shift of +4.6 °C was observed for the target kinase at 10 µM compound concentration.

In materials chemistry, the electron-deficient thiazole ring activated by both bromine and aldehyde enables its incorporation into donor–acceptor copolymers via polycondensation. The comonomer 2,5-bis(trimethylstannyl)thiophene was polymerized with 4-bromo-1,3-thiazole-2-carboxaldehyde under Stille coupling conditions in a microwave reactor (Biotage Initiator+, absorption level High, 120 °C, 45 min, toluene/DMF 4:1, Pd₂(dba)₃/P(o-tol)₃ 2 mol%). The resulting alternating copolymer displayed a number-average molecular weight (M_n) of 12.3 kDa and a polydispersity index of 1.8 (GPC in THF vs. polystyrene standards, ASTM D6474-12). Optical bandgap determined by the onset of UV-Vis absorption in thin film was 1.92 eV. Crucially, residual aldehyde end-groups left after the polymerisation act as defect sites that trap charge carriers; end-capping with 2-(tributylstannyl)thiophene (5 eq) after polymerisation reduced the non-radiative recombination pathways and increased the hole mobility measured by space-charge-limited current (SCLC) technique from 2.1 × 10⁻⁵ to 8.7 × 10⁻⁵ cm² V⁻¹ s⁻¹. Film annealing was intentionally restricted to 150 °C because the C‒Br thermal stability limit, as determined by TGA-FTIR, shows onset of HBr evolution at 172 °C, which would generate voids and crosslink sites in the active layer.